Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
Every day, people living with cancer come to Stanford for help, hope and healing.
.jpeg)
The Future of Cancer
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still!
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
Racial diversity in clinical trials: Barriers and opportunities
The Stanford Cancer Institute (SCI) prioritizes the inclusion of diverse patients from underrepresented backgrounds in cancer clinical research.
The Stanford Cancer Institute (SCI) mourns the passing of our beloved SCI member Shoshana Levy, PhD.
Stanford's CAR22 therapy granted breakthrough designation by FDA
Stanford Cancer Institute members Matthew Frank, MD, PhD, and David Miklos, MD, PhD, have received FDA breakthrough therapy designation on a trial using CAR22 to treat patients with relapsed/refractory large B-cell lymphoma that has progressed after prior CAR19 therapy.
Laura Attardi receives the NCI Outstanding Investigator Award
Congratulations to SCI member Laura Attardi, PhD, on receiving The National Cancer Institute Outstanding Investigator Award!
Cancer Clinical Trials
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.